Underweight: 33% trim into strength, anchored at $83 stop, Q2 FY27 print as binary re-engagement catalyst
Underweight with 33% trim executed into strength, anchored at $83.00 daily-close stop. The bearish thesis rests on three evidence pillars: (1) September 30 breakdown through 200 SMA ($87.24) on 26.6M shares — heaviest volume in 13 months (textbook distribution); (2) 13.47x forward P/E embeds heroic $6.41 forward EPS requiring step-function growth from $1.07 Q2-FY26 base; (3) Buybacks collapsed 68% YoY ($3.24B → $1.04B), signaling management does not view $86 as repurchase-worthy. Q2 FY27 print is the mandatory re-evaluation trigger — rebuild 15-20% on >+12% print with technical confirmation; exit on <+8% print or margin compression. Sell rejected due to dividend safety, 115% FCF coverage, 3.3% yield, and multi-platform pipeline providing asymmetric floor. Hold rejected per 9/28/9/22 lessons — waiting for lagging SMA confirmation while fundamentals deteriorate systematically bleeds alpha.
| Position | Action |
|---|---|
| Relief bounce toward $88-$90.50 resistance confluence | Trim ~33% of MDT exposure |
| No relief bounce within 3-5 sessions | Execute remaining balance at market to honor pre-committed architecture |
| Q2 FY27 print >+12% with technical confirmation | Rebuild 15-20% of position |
| Q2 FY27 print <+8% or margin compression | Exit remaining position |
MDT is a mean-reversion long setup where technical weakness (RSI 37.56, price below 200 SMA) has created a mechanically-forced entry point on a fundamentally accelerating business trading at 13.47x forward earnings with a 3.31% dividend yield.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | $87.24 | bearish |
| close_50_sma | $89.07 | bearish |
| close_10_ema | $88.82 | bearish |
| rsi | 37.56 | bearish |
| macd | -0.53 | bearish |
| macdh | -0.70 | bearish |
| boll_middle | $90.56 | neutral |
| boll_upper | $94.60 | neutral |
| boll_lower | $86.53 | bullish |
| vwma | $89.60 | bearish |
| atr | $2.06 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: No relief bounce materializes within 3-5 sessions
Then: Execute remaining balance at market
RSI 37.56 without hitting oversold threshold signals mean-reversion is imminent, not continued downside
↩ rebuts: “Bear's RSI argument suggesting further downside risk remains”
EV: +7.8% to $93 (Sept 2026 high retest) / +10.1% to $95
The September 30 technical breakdown through the 200 SMA on record volume despite positive catalysts (LigaSure RAS clearance, $700M Cornerstone deal, +13.7% Q1 print) represents the market repricing MDT from "growth re-acceleration at 18-20x" to "structurally challenged large-cap device with execution risk at 13-15x" — the cheap forward multiple IS the bear case.
EV: -$7 to $8 (downside to $83-84 base case, $78-79 extended)
→ vs conservative: The 3.2% yield does not cushion against capital loss when technicals are broken, insider behavior confirms skepticism, and the 91% payout ratio has zero margin for earnings disappointment
→ vs conservative: Partnership announcements like Cornerstone Robotics are not bullish catalysts but admissions of weakness — MDT is hedging Hugo because it cannot dethrone da Vinci on narrative alone
→ vs neutral: The double-digit F1Q27 print is not an inflection but a step-function requiring three consecutive quarters of ~$1.76 EPS against a $1.07 base, which management's own buyback pullback does not support
→ vs neutral: Waiting for tape confirmation means buying after the 200-day break already occurred; the signal has been given and positioning is already shifted
Support: 86.53 · 83 · 84 · 78 · 79 | Resistance: 94.6 · 90.56 · 89.07 · 89.6 · 88.8 · 87.24
MDT exhibits a full bearish breakdown with price ($86.29) below all three moving averages (200 SMA at $87.24, 50 SMA at $89.07, 10 EMA at $88.82) and the lower Bollinger band ($86.53); RSI at 37.56 has fallen 27 points in 19 sessions without reaching oversold territory, while MACD has crossed below zero and is accelerating negative (histogram -0.70); volume of 26.6M shares on Sep 30 marks the heaviest session in 13 months, confirming distribution rather than accumulation, with VWMA ($89.60) sitting $3.31 above current price, indicating forced selling from underwater holders; layered resistance at $88.80–$90.60 creates a sell-into-strength zone, with support at the lower band $86.53, then $83–$84, and prior capitulation low at $78–$79.
Market Cap
$110.4 B
Current Price
~$86.2
P/E (TTM)
21.25x
Forward P/E
13.47x
PEG Ratio
1.56
Price / Book
2.20x
Book Value / share
$39.24
Dividend Yield
3.31%
Beta
0.574
52-Week High
$106.33
52-Week Low
$73.31
50-Day MA
$89.66
200-Day MA
$88.84
Diluted EPS (TTM)
$4.06
Forward EPS
$6.41
FY26 Revenue
$36.36 B
FY26 Revenue YoY Growth
+8.4%
FY26 Gross Profit
$23.64 B
FY26 Gross Margin
65.0%
FY26 Operating Income
$6.83 B
FY26 Op Margin
18.8%
FY26 Net Income
$4.80 B
FY26 Net Margin
13.2%
FY26 Diluted EPS
$3.73
FY26 R&D
$2.87 B (~7.9% of rev)
FY26 SG&A
$11.78 B
FY26 Effective Tax Rate
21.2%
FY26 Operating Cash Flow
$7.33 B
FY26 Capital Expenditure
($1.90) B
FY26 Free Cash Flow
$5.43 B
FY26 Dividends Paid
($3.64) B
FY26 Buybacks
($1.04) B
FY26 Net Debt Issuance / (Repayment)
($1.17) B
Q1 FY27 Revenue
$9.756 B (+13.7% YoY)
Q1 FY27 EPS
$1.14
Q1 FY27 Operating Margin
18.8%
Q1 FY27 FCF
$1.29 B
Gross Margin (TTM)
65.3%
Operating Margin (TTM)
19.3%
Net Profit Margin (TTM)
13.9%
Return on Equity (TTM)
10.6%
Return on Assets (TTM)
5.1%
EBITDA Margin (TTM)
~27.7%
FCF / Revenue
~14.4%
Annual Dividend
~$3.68
Dividend Payout Ratio
~91% (FCF covered)
FCF / Share
~$4.23
Q1 FY27 Total Assets
$93.31 B
Q1 FY27 Cash & ST Inv.
$8.82 B
Q1 FY27 Total Debt
$28.15 B
Q1 FY27 Net Debt
$26.41 B
Q1 FY27 Stockholders' Equity
$50.23 B
Q1 FY27 Goodwill + Intangibles
$53.42 B
Q1 FY27 Net Tangible Assets
($3.19) B
Q1 FY27 Working Capital
$12.59 B
Q1 FY27 Current Ratio
2.07
Q1 FY27 Debt / Equity
0.56
Net Debt / EBITDA
~2.5x
Strengths
Concerns
Medtronic is a high-quality, defensive, dividend-paying compounder currently in a fundamental reacceleration phase following several years of sluggish low-single-digit growth. Revenue growth has stepped up to high-single/low-double digits, margins are stable-to-improving, FCF generation is robust at $5.43B, and the balance sheet is investment grade. The stock trades at a meaningfully discounted forward multiple (13.47x) while offering a 3.31% dividend yield, with technicals showing a base near the 200-day MA. Best suited for dividend + modest capital appreciation, not aggressive upside capture.
Macro: The week of Sept 23–30, 2026 was defined by a sharp backup in long-dated Treasury yields, with the 30-year Treasury hitting its highest level since 2002. The 30-year fixed mortgage rate rose to 7.58%, approaching a 3-year high, directly pressuring housing and household balance sheets that fund out-of-pocket healthcare spending. Prediction markets confirm higher-for-longer Fed expectations with 97% implied probability of zero rate cuts in 2026 (~$8.7M volume) while pricing only 8% recession probability by end of 2026 — indicating a stagnationary, sticky-inflation regime rather than recession. Equities ended the week modestly green but September was net negative for the S&P 500 and Dow.